Summary
Global Markets Direct’s, ‘Thymus Cancer - Pipeline Review, H1 2016’, provides an overview of the Thymus Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thymus Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thymus Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
- The report reviews pipeline therapeutics for Thymus Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thymus Cancer therapeutics and enlists all their major and minor projects
- The report assesses Thymus Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thymus Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Cellceutix Corporation
Merck & Co., Inc.
Novartis AG
Onxeo SA
Sumitomo Dainippon Pharma Co., Ltd.
Taiwan Liposome Company, Ltd.
Tiziana Life Sciences Plc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thymus Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Thymus Cancer - Overview 7
Thymus Cancer - Therapeutics under Development by Companies 8
Thymus Cancer - Pipeline Products Glance 9
Clinical Stage Products 9
Thymus Cancer - Products under Development by Companies 10
Thymus Cancer - Companies Involved in Therapeutics Development 11
Cellceutix Corporation 11
Merck & Co., Inc. 12
Novartis AG 13
Onxeo SA 14
Sumitomo Dainippon Pharma Co., Ltd. 15
Taiwan Liposome Company, Ltd. 16
Tiziana Life Sciences Plc 17
Thymus Cancer - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
amrubicin hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
belinostat - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
buparlisib hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
KM-3174 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
milciclib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MK-2206 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MK-2206 + selumetinib sulfate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pasireotide ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pembrolizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TLC-388 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Thymus Cancer - Recent Pipeline Updates 64
Thymus Cancer - Dormant Projects 104
Thymus Cancer - Product Development Milestones 105
Featured News & Press Releases 105
Aug 11, 2015: Cellceutixs Kevetrin and Thymoma — a Rare Cancer 105
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 105
May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 106
Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas 106
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 108
Disclaimer 109
List of Tables
Number of Products under Development for Thymus Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Products under Development by Companies, H1 2016 10
Thymus Cancer - Pipeline by Cellceutix Corporation, H1 2016 11
Thymus Cancer - Pipeline by Merck & Co., Inc., H1 2016 12
Thymus Cancer - Pipeline by Novartis AG, H1 2016 13
Thymus Cancer - Pipeline by Onxeo SA, H1 2016 14
Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 15
Thymus Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 16
Thymus Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Assessment by Combination Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Thymus Cancer Therapeutics - Recent Pipeline Updates, H1 2016 64
Thymus Cancer - Dormant Projects, H1 2016 104
List of Figures
Number of Products under Development for Thymus Cancer, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Top 10 Targets, H1 2016 20
Number of Products by Stage and Top 10 Targets, H1 2016 20
Number of Products by Top 10 Mechanism of Actions, H1 2016 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22
Number of Products by Top 10 Routes of Administration, H1 2016 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 24
Number of Products by Top 10 Molecule Types, H1 2016 26
Number of Products by Stage and Top 10 Molecule Types, H1 2016 26
